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Presence of neuritic plaques and neurofibrillary tangles in the brain are two neuropathological hallmarks of Alzheimer's disease (AD),
although the molecular basis of their coexistence remains elusive. The neurofibrillary tangles are composed of microtubule binding protein Tau,
whereas neuritic plaques consist of amyloid-β peptides derived from amyloid precursor protein (APP). Recently, the peptidyl-prolyl cis/trans
isomerase Pin1 has been identified to regulate the function of certain proteins after phosphorylation and to play an important role in cell cycle
regulation and cancer development. New data indicate that Pin1 also regulates the function and processing of Tau and APP, respectively, and is
important for protecting against age-dependent neurodegeneration. Furthermore, Pin1 is the only gene known so far that, when deleted in mice,
can cause both Tau and Aβ-related pathologies in an age-dependent manner, resembling many aspects of human Alzheimer's disease. Moreover,
in the human AD brain Pin1 is downregulated or inhibited by oxidative modifications and/or genetic changes. These results suggest that Pin1
deregulation may provide a link between formation of tangles and plaques in AD.
© 2007 Elsevier B.V. All rights reserved.Keywords: Pin1; Isomerase; APP; Tau; Phosphorylation; Alzheimer's disease; Neurodegeneration1. Pin1 in cell cycle regulation and cancer
Transition through the cell cycle in eukaryotic cells is
regulated by highly orchestrated and intertwined processes of
protein synthesis, degradation and post-translational modifica-
tion. For its rapid activating/inhibiting effect, phosphorylation
of regulatory molecules by cell cycle kinases plays a key role
among the post-translational processes. Several families of the
cell cycle kinases can be distinguished, the most prominent
being cyclin dependent kinase (cdk), Polo, aurora and never in
mitosis A (NIMA) families (for review see [1]). Activation of
the protein kinases during the cell cycle triggers phosphoryla-
tion cascades that drive transition from one phase of the cell
cycle to another. For example, activation of the cyclin-
dependant kinase Cdc2 during the G2/M transition leads to
phosphorylation of a large number of proteins on Ser/Thr-Pro
motifs, which has been shown in some cases to regulate mitotic
events [2–4].⁎ Corresponding author.
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doi:10.1016/j.bbadis.2007.01.006With the discovery of Pin1, another level of cell cycle
regulation has been uncovered [5]. Pin1 has been originally
identified as a binding partner and suppressor of the mitotic
kinase NIMA [5]. It contains two functional domains, an N-
terminal WW domain and a C-terminal peptidyl-prolyl cis/
trans isomerase (PPIase) domain [5–7]. The WW domain is a
phosphorylation-specific protein interaction module that
directs Pin1 to its substrates—proteins phosphorylated at a
certain serine or threonine residue followed by proline (pSer/
Thr-Pro motif) [7–9]. Upon this binding, the PPIase domain
catalyzes conformational change of the Pin1 substrates by
isomerizing specific pSer/Thr-Pro bonds [6,10]. The specific
binding to and isomerization of pSer/Thr-Pro motifs distin-
guishes Pin1 from the other known PPIase families such as
cyclophilins and FK506-binding proteins. To date, Pin1-type
PPIases are the only known pSer/Thr-Pro-specific isomerases
[5,7,8]. The isomerization of pSer/Thr-Pro motifs represents
an important regulatory mechanism since several protein
kinases (e.g. CDK2, MAPK) and phosphatases (e.g. PP2A)
are conformation specific, recognizing only trans Ser/Thr-Pro
isomers [10–12]. Furthermore, phosphorylation slows the
already protracted isomerization reaction of Ser/Thr-Pro bonds
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catalytic action of cyclophilin, FKBP or parvulin [8,14]. Thus,
conformation of a Ser/Thr-Pro motif can have a profound
effect on phosphorylation signaling.
Due to a large number of Pin1 substrates, Pin1 is involved in
multiple cellular processes. The discovery of Pin1's regulatory
function in the cell cycle and signaling has been followed by its
important function in DNA damage responses, transcription,
splicing, and germ cell development [5,6,9,10,15–32]. The
involvement of Pin1 in the regulation of the cell cycle, cell
signaling and responses to DNA damage suggests that its
deregulation might contribute to some medical conditions in
humans. Indeed, Pin1 is overexpressed in many tumors and its
overexpression correlates with poor clinical outcome [20,33–
35]. Furthermore, Pin1 is an E2F target gene that is critical for
activation of multiple upstream oncogenic pathways [20,21,27,
33,36,37] and also for coordination of some downstream cell
cycle events such as centrosome duplication [38]. Moreover,
Pin1 overexpression results in centrosome amplification and
tumorigenesis in vitro and in vivo [38]. In contrast, Pin1
knockout in mice prevents certain oncogenes from inducing
tumors [39] and Pin1 knockout in cancer cells suppresses cell
growth in vitro and tumor growth in vivo [40]. These and other
results indicate that Pin1 plays a major role in cancer develop-
ment and is an attractive anticancer target [41,42].
2. Pin1 in Alzheimer's disease
Many phospho-proteins recognized by Pin1 are recognized
also by a phospho-specific monoclonal antibody mitotic phospho-
protein monoclonal-2 (MPM-2), which strongly reacts with
mitotic protein extracts [43] and with neurofibrillary tangles
(NFTs), neuritic processes, and neurons in the brains of
Alzheimer disease (AD) patients [44–46]. Re-appearance of
the MPM-2 epitopes in the AD brains is concomitant with
aberrant expression of some kinases, e.g. Cdc2-a mitotic kinase
phosphorylating Ser/Thr-Pro motif during the G2/M phase of the
cell cycle but absent in the healthy brain [45]. Consequently,
while in the healthy brains Pin1 is expressed mainly in the
neuronal soluble fraction [5,20,32,47,48], in the brains of AD
patients it co-localizes and co-purifies with NFTs resulting in
depletion of soluble Pin1 [47,48,50]. Moreover, Pin1−/− mice
develop progressive age-dependent neuropathy characterized by
Tau hyper-phosphorylation, Tau filament formation, amyloid
precursor protein (APP) amyloidogenesis, intracellular Aβ42
accumulation and neuronal degeneration [51,52]. Pin1 inhibi-
tion in the brain, therefore, may be an important factor in
development of neurodegenerative disorders and AD, in
particular. In the following section we will focus on the role
of Pin1 in Tau- and APP-related pathologies.
2.1. Pin1 and tauopathies
Tauopathies are a heterogeneous group of diseases char-
acterized by the presence of NFTs, a pathological structure
composed of hyper-phosphorylated microtubule-associated
protein Tau organized in dense arrays of paired helical filaments(PHFs). NFTs have been discovered in AD, frontotemporal
dementia parkinsonism linked to chromosome 17 (FTDP-17),
progressive supranuclear palsy (PSP) Pick disease and cortico-
basal degeneration (for review see [53]). Even though the
presence of hyper-phosphorylated Tau is clearly pathological, it
has been a matter of debate whether it causes the diseases or
whether it is a consequence of a common pathologic process.
The fact that Tau mutations have been found in patients
suffering from FTDP-17 indicates that at least in some cases
mutant Tau can trigger a disease [54–56]. Several mouse
models have been created mimicking pathologic features of
human tauopathies. Overexpression of human wild-type Tau or
especially Tau FDTP-17 mutants causes progressive and age-
dependent formation of NFTs in mice [57–59]. Transgenic mice
overexpressing a different version of human Tau (namely the
smallest isoform, four repeats of microtubule domain isoform,
Pro301Leu mutant, Arg406Trp mutant, or Val337Met mutant)
all exhibit hyper-phosphorylation of Tau [57–63], although
different mutations or splice variants of Tau have demonstrated
different levels and patterns of neuronal loss or axonal
degeneration in brain and spinal cords [57–63].
Tangle formation in AD appears to be preceded by increased
phosphorylation of Tau and other proteins on serine or threonine
residues followed by proline (pSer/Thr-Pro). Even though the
exact role of hyper-phosphorylation for development of tauo-
pathies has not been clearly defined, analysis of transgenic
mouse models overexpressing p25 activator of CDK5 kinase has
shown that an increased phosphorylation can induce tauopathy
in mice [64]. Importantly, hyper-phosphorylated Tau can activate
mitotic signaling pathways [65], as demonstrated in Drosophila.
Since re-entry into the cell cycle is toxic for neurons, and
activation of CDKs and other mitotic proteins has been cor-
related with neurodegeneration in AD proteins (reviewed by
[66]), hyper-phosphorylated Tau activating mitotic signaling
could in some cases lead to neuronal cell death independent of
NFT formation. Hyper-phosphorylation of Tau may trigger
multiple cellular responses. These include cell cycle re-entry and
deposition of NFTs since there are many phosphorylation sites
on Tau protein which may interact with various signaling
molecules contributing separately or in combination to neuronal
toxicity. Notably, among the phosphorylation sites in Tau there
are 15 pSer/Thr-Pro motifs [67], i.e. putative Pin1 binding sites.
Pin1 binds to Tau in a phosphorylation-dependent manner
specifically to its pThr231 residue [48,68]. Interestingly, the
levels of Tau-P-T231 have been shown to correlate with the
progression of the AD [69,70]. Upon its binding to pThr231
Pin1 catalyzes cis/trans isomerization of pSer/Thr-Pro, thereby
inducing conformational changes in Tau. Such conformational
changes can directly restore the ability of phosphorylated Tau to
bind microtubules and promote microtubule assembly [71] and/
or facilitate Tau dephosphorylation by its phosphatase PP2A, as
PP2A activity is conformation-specific [10]. Hamdane et al.
recently showed that Pin1 level was strongly increased during
neuronal differentiation and tightly correlated with Tau depho-
sphorylation at Thr231 [72]. In their cellular model, Pin1
facilitated Tau dephosphorylation of Thr231 specifically,
whereas other phosphorylation sites were not affected by Pin1
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overexpressing animal models, would be of a great interest.
When Pin1 protein was analyzed in human brain using
immunohistochemical staining, its expression in normal brain
was relatively higher in hippocampal CA3, CA2 and CA4
regions and in presubiculum and lower in hippocampal CA1
region and subiculum [51]. In the parietal cortex, expression of
Pin1 is relatively higher in layer IIIb-c neurons and lower in
layer V neurons [51]. In the AD brain, Pin1 expression in the
hippocampus and parietal cortex is relatively high in tangle-
sparing subregions, but low in the tangle-rich subregions. [51].
Furthermore, even within the tangle-prone CA1 region and
subiculum of the hippocampus, Pin1 expression in most tangle-
bearing neurons is still relatively lower than that in tangle-free
neurons [51]. Thus, Pin1 expression level is inversely correlated
with the neuronal vulnerability to degeneration in normal brain
and with actual neurofibrillary degeneration in AD brain.
The significance of the differential Pin1 expression is further
demonstrated by analyzing neuronal phenotypes of Pin1
knockout mice. Pin1 knockout mice develop normally but they
suffer from progressive retinal degeneration with the onset at
around 4–6 months [21]. Aged Pin1−/− mice, but not their wild-
type littermates, show progressive age-dependent motor and
behavioral deficits, which include abnormal limb-clasping
reflexes, hunched postures, and reduced mobility [51]. These
deficits have also been reported in Tau transgenic mice studies
[58,73]. The phenotype seems to be caused by neuronal loss as
the number of neurons is significantly decreased in the parietal
cortex and spinal cord of old (over 1 year), but not young Pin1−/−
mice. Correspondingly, Tau hyperphosphorylation has been
observed in aged Pin1−/− mice [51]. The various phosphorylated
forms of Tau in Pin1−/− mice were also detected by a range of
phospho-specific or Alzheimer-conformation-specific antibo-
dies, such as AT180 and TG3 [51]. In aged Pin1−/− mice,
immunohistochemical staining of the hippocampus, cortex and
spinal cord with specific pTau antibodies showed pathological
localization of Tau in soma and dendrites of neurons [51]. The
hyper-phosphorylation of Tau eventually leads to Tau aggrega-
tion and Tau filament formation in Pin1−/− mice [51].
Additionally, NFT-like Tau filaments decorated by AT180 gold
label can be isolated from sarkosyl insoluble fractions of Pin1−/−
mice [51]. The entorhinal cortex and hippocampus, two brain
regions which show prominent degeneration in AD, were
strongly immunopositive for stains that label NFTs including
Gallyas and thioflavin-S in Pin1−/− mice [51].
Together with the in vitro data, analysis of Pin1−/− mice
demonstrates that Pin1 regulates the function of Tau both in vivo
and in vitro likely through catalysis of its conformational change.
Importantly, Tau hyperphosphorylation and NFT formation can
be induced by Aβ challenge and/or PS1 mutation [74–78]. Thus,
Pin1 functioning in APP processing could also contribute to the
development of Tau phenotypes in Pin1−/− mice.
2.2. Pin1 and APP processing and Aβ production
APP is a transmembrane protein consisting of a large extra-
cellular and short transmembrane and intracellular domains. Itcan be processed by two alternative pathways: non-amyloido-
genic, which involves cleavage by α-secretase, or amyloido-
genic, which involves cleavage by β- and γ-secretases and leads
to production of plaque forming β-amyloid peptides (Aβ) (for
review see [79]). Several factors can influence APP processing
and shift it towards amyloid/non-amyloid pathway. Recently,
phosphorylation of APP has been found to be one of those
factors [52,80,81].
To date only four phosphorylation sites have been confirmed
at the intracellular domain of APP: S655, T654, T668, and
Y682 [82–86]. Even though APP has not been identified as an
MPM-2 epitope, it does contain a pThr-Pro motif (T668) which
has been shown to be phosphorylated during mitosis by CDC2
[83,87], in neurons by CDK5 [88] and in vitro by GSK-3β [89]
and which is located at the consensus Pin1 binding sequence
[8,9]. In addition, APP has been found to undergo a
conformational change following phosphorylation of T668
[90] making it a promising candidate for a Pin1 substrate.
Indeed, we have shown that Pin1 interacts with APP isolated
from mitotic cells and that the interaction is phosphorylation
dependent [52]. Furthermore, direct NMR measurement
demonstrated that Pin1 catalyzes the cis/trans isomerization
of pThr668-Pro [52], since it accelerates both kcis to trans
cat and
ktrans to cis
cat by over 1000 fold over the typical uncatalyzed
isomerization rates for pThr-Pro peptides [13]. The catalyzed
cis to trans rate is 10-fold faster than the catalyzed trans to
cis rate [52]. Change of the conformation of pThr668-Pro
may represent an important regulatory mechanism since it may
influence the interaction between APP and its binding partners
such as Fe65. The binding of Fe65 to APP has been shown to be
phosphorylation-dependent through pT668 residue of APP and
to influence production of Aβ [91]. Thus, Pin1 may have a
direct impact on this regulatory process.
Pin1 subcellular localization is driven by the presence of its
substrates [6,31,92,93]. Processing of APP, an integral
membrane protein, is influenced by APP subcellular localiza-
tion and occurs through non-amyloidogenic α-secretases
mainly at the plasma membrane and amyloidogenic β-
secretases at endosomes and other subsequent structures [94–
98]. Recently, it has been shown that Pin1 co-localizes with
APP primarily in vesicles localized at the plasma membrane and
in AP-2 coated clathrin-coated vesicles, but not at endosomes
[52]. This suggests that Pin1 may influence APP intracellular
localization, affecting its processing and Aβ production. This
hypothesis has been corroborated by additional data. In the cell
culture experiments, overexpression of Pin1 has been shown to
reduce Aβ secretion, and its effect was particularly pronounced
in the mitotic cells where Thr668 phosphorylation was
increased [52].
Sequential proteolysis of APP by β- and γ-secretases
generates mainly 40- and 42-residue Aβ peptides (Aβ40 and
Aβ42). While Aβ40 is a major secreted product, Aβ42 is more
toxic and is the major contributor to the plaque formation in AD
brains [96–98]. Familial AD-linked (FAD) mutations in the
APP or presenilin genes selectively increase Aβ42 levels in
humans and mice [99–102]. Pin1 ablation seems not to have a
significant effect on soluble Aβ40 or Aβ42 levels, but we found
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Pin1+/+ littermates [52]. Additionally, Pin1 ablation causes
prominent localization of Aβ42 to multivesicular bodies
(MVB) [52], as in human AD and APP-Tg2576 mice before
β-amyloid plaque pathology [103]. Thus, although it is not clear
yet whether and how Aβ42 at MVB contributes to plaque
formation, the data suggest that Pin1 may be involved in Aβ-
related pathology.
Strong support for a direct role of Pin1 in APP processing
came from analysis of a classic mouse AD model: APP-Tg2576
mice overexpressing the human APP KM670/671NL (Swedish)
mutant [76]. APP processing is initiated by either non-
amyloidogenic α- or amyloidogenic β-secretases, which cleave
the extracellular/lumenal domain, generating soluble NH2-
terminal fragments, αAPPs or βAPPs, and a membrane-
anchored 83-residue or 99/89-residueCOOH-terminal fragments
(αCTFs or βCTFs), respectively [94–98]. In APP-Tg2576
mouse brains, Pin1 deletion leads to a significant increase of
soluble total APPs and βAPPs, but to a decrease of αAPPs in an
age-dependent manner [52]. More importantly, these age-Fig. 1. Pin1 catalyzes cis to trans conformational change of APP phosphorylated at T
isomerization of pT668-P and pT231-P is shifted towards the trans conformation, whi
In Alzheimer's disease (B), downregulation, oxidation or mutation of Pin1 reduces
pathway and increase Aβ production. In the case of Tau, reduced isomerization rate
NFTs and pathological re-entry into cell cycle.dependent effects are also accompanied by the age-dependent
increase in insoluble Aβ42 [52]. Thus, Pin1 depletion seems to
favor the amyloidogenic versus non-amyloidogenic processing
of APP.
The view of Pin1 as an important factor contributing to
development of AD has been supported by several studies.
Recently, a new genetic locus associated with late-onset AD has
been identified on chromosome 19p13.2 where the Pin1 gene is
located [104]. Furthermore, the Pin1 promoter polymorphisms
at − 842 bp and − 667 bp have been found to be associated with
reduced Pin1 levels and increased risk for late-onset AD in
Italian cohorts [105], although apparently not in French cohorts
[106]. Moreover, proteomic approaches have confirmed down-
regulation of Pin1 in AD neurons, and also uncovered that Pin1
is inhibited by oxidation in AD hippocampus even in patients
with mild cognitive impairment [107,108]. Finally, our findings
of the opposite effects of Pin1 on the pathogenesis of cancer
versus on AD suggest an interesting inverse relationship
between these two major age-dependent diseases, which is
also supported by an epidemiological study [109]. Roe et al.668-P and Tau phosphorylated at T231-P. In the presence of functional Pin1 (A)
ch promotes non-amyloidogenic cleavage of APP and dephosphorylation of Tau.
the isomerization rate that may, in the case of APP, promote the amyloidogenic
may promote aggregation of hyperphosphorylated Tau, inducing formation of
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participants with Alzheimer type dementia versus non-demen-
ted participants and that the risk of developing Alzheimer type
dementia may be lower for participants with a history of cancer
[109]. Together these results indicate that Pin1 inhibition may
be an important contributing factor to the development of AD.
2.3. A model of the role of Pin1 in the healthy and Alzheimer’s
neurons
The above results suggest a model of the function of Pin1 in
the healthy and AD neurons (Fig. 1): In the healthy neurons
(Fig. 1A), Pin1 binds to Tau and APP after their phosphoryla-
tion at Thr231 or Thr668, respectively (which drastically slows
down their cis to trans isomerization) and greatly accelerates
their cis to trans isomerization rates, thereby inducing
conformational changes. This might facilitate dephosphoryla-
tion of Tau, and promote the non-amyloidogenic pathway and
reduce Aβ production (presumably through affecting APP
intracellular localization and its interactions with specific
binding partners). However, under pathological conditions
(Fig. 1B), Pin1 function may be absent as in Pin1−/− mice or
inhibited as seen in AD (due to down-regulation, oxidation of
and/or genetic changes in Pin1, or relatively due to excess APP
phosphorylation caused by upstream regulators including over-
activation of JNKs, Cdks and/or GSKs). In these cases,
isomerization rate of pThr231-Pro of Tau and pT668-Pro of
APP may be reduced, which may lead to accumulation of
phosphorylated Tau and promote the amyloidogenic pathway of
APP. Increased levels of phosphorylated Tau may lead to tangle
formation as well as trigger pathological re-entry into the cell
cycle and cell death of the affected neurons, as demonstrated in
the Drosophila model [65], while increased Aβ production
might enhance the plaque pathology.
3. Conclusions
Neurofibrillary tangles and senile plaques are two neuron-
pathological hallmarks of AD, but the molecular basis of their
coexistence remains elusive. Recent results indicate that the
peptidyl-prolyl cis/trans isomerase Pin1 acts on both Tau and
APP to regulate their dephosphorylation, processing and
biological function [51,52]. Furthermore, loss of Pin1 function
in mice can cause both Tau and Aβ-related pathologies in an
age-dependent manner, resembling many aspects of human
Alzheimer's disease [51,52]. As a support for the deleterious
effect of Pin1 depletion, Pin1 has been found to be oxidized and
inhibited in AD brains even with mild cognitive impairment
[107,108] and AD neurons have been shown to be depleted of
the soluble form of Pin1 [48,49]. Moreover, the Pin1 promoter
polymorphisms have been found to be associated with reduced
Pin1 levels and an increased risk for late-onset AD in a certain
population [105]. Thus, Pin1 plays a pivotal role in protecting
against age-dependent neurodegeneration, and Pin1 down-
regulation or inhibition may provide a link between tangle and
plaque formation in AD. While it is possible that depletion of
Pin1 modulates additional AD related molecular pathways, itsimpact on the function and metabolism of the two major AD
related molecules Tau and APP is likely an important factor in
AD development. Furthermore, since the ablation of the Pin1
gene alone or in combination with mutant APP overexpression
leads to the age-dependent accumulation of insoluble Aβ42 in
multivesicular bodies of neurons, an early sign of plaque
pathology in human AD, it can be speculated that Pin1 plays a
role in the initial steps of β-amyloid pathology and plaque
formation. Moreover, Pin1 prevents tau hyperphosphorylation,
which again precedes tangle formation and neurodegeneration.
These findings suggest that Pin1 may be an attractive new target
to be modulated for the treatment of Alzheimer's disease at
early stages. Further analysis of the regulation of Pin1
expression in neurons will be necessary to achieve this goal.
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